Anzeige
Mehr »
Login
Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von MedCity News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
00:46Talkiatry Raises $130M To Expand Behavioral Health Access
Di3 Things to Know About the Cybergang that Attacked Ascension
Di9 Requirements for an Optimal Genetic Test Benefit Program
DiCancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug
DiInnovation Alone Isn't Enough: Addressing the Legacy of Administrative Burdens in Healthcare
DiIs There a Doctor on the Plane?
DiIf Passed, This New Bill Could Send PE Execs to Jail for Hospital Mismanagement
MoHealthcare Execs' Urgent Calls To Action
MoTakeda Drug Fails Pivotal Tests in 2 Rare Epilepsies; Path Forward Depends on Regulatory Flexibility
MoWhy Conditions are Ripe for Enabling Care Everywhere
MoAre GLP-1 Drugs Here to Stay?
MoFive Keys for the Successful Implementation of a State-Based Marketplace
SoIs Corporatization Killing Primary Care?
SoThese 3 Things Must Change for Hospital Cybersecurity to Improve
SoWhy Walgreens' US Health President Is 'Bullish' on the Role of Retail in Healthcare
SoTelehealth Can Broaden Reach of Palliative Care for Lung Cancer Patients, Per MGH Study
FrNew FDA Nod Brings Bristol Myers Squibb Cancer Drug to a Wider Range of Solid Tumors
FrWheel's New AI Platform Seeks to Power the New Era of Virtual Care
FrBetter Health Raises $14M To Reach More Patients with Chronic Conditions
FrAddressing Healthcare Workforce Shortages Beyond Band-Aids
FrFrom Recalls to Reliability: Tools to Ensure Software Safety in MedTech
FrHow Healthcare Leaders Are Reacting to the Supreme Court Preserving Abortion Pill Access
FrAmeriHealth Caritas Exec: Worst Thing Insurers Can Do Is Be Paralyzed by AI Challenges
DoPfizer & Sarepta Gene Therapies Both Failed Phase 3, But Analysts Expect Sarepta Will Win Approval
DoHow Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs